NCT06762769
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06762769
Title Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma (MODIFY)
Acronym MODIFY
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications
Therapies
Age Groups: senior | adult
Covered Countries GBR

Facility Status City State Zip Country Details
St James University Hospital RECRUITING Leeds Leeds LS9 7TF United Kingdom Details
Churchill Hospital RECRUITING Oxford Oxford OX3 7LE United Kingdom Details
Aberdeen Royal Infirmary RECRUITING Aberdeen AB25 2ZN United Kingdom Details
University of Birmingham Hospital RECRUITING Birmingham B15 2GW United Kingdom Details
Bristol NHS Foundation Trust RECRUITING Bristol BS10 5NB United Kingdom Details
Cardiff and Vale University Health Board RECRUITING Cardiff CF14 4HH United Kingdom Details
University Hospitals of Derby and Burton RECRUITING Derby DE22 3NE United Kingdom Details
Barts Health Trust RECRUITING London EC1A 7BE United Kingdom Details
University College London Hospital RECRUITING London NW1 2PB United Kingdom Details
King's College Hospital NHS Foundation Trust RECRUITING London SE5 9RS United Kingdom Details
St Georges Hospital RECRUITING London SW17 0QT United Kingdom Details
Nottingham City Hospital RECRUITING Nottingham NG5 1PB United Kingdom Details
George Eliot Hospital RECRUITING Nuneaton CV10 7DJ United Kingdom Details
Glan Clwyd Hospital RECRUITING Wales LL18 5UJ United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field